---
title: "aTyr Pharma, Inc. (ATYR.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ATYR.US.md"
symbol: "ATYR.US"
name: "aTyr Pharma, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T20:16:45.370Z"
locales:
  - [en](https://longbridge.com/en/quote/ATYR.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ATYR.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ATYR.US.md)
---

# aTyr Pharma, Inc. (ATYR.US)

## Company Overview

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [atyrpharma.com](https://atyrpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: D (0.67)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 285 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | -10.43% |  |
| P/B Ratio | 0.88 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 50937604.63 |  |
| Revenue | 190000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -105.32% | E |
| Profit Margin | -36857.37% | E |
| Gross Margin | 0.00% | E |
| Revenue YoY | 0.00% | D |
| Net Profit YoY | -10.43% | D |
| Total Assets YoY | -18.09% | E |
| Net Assets YoY | -22.87% | E |
| Cash Flow Margin | 84.37% | C |
| OCF YoY | 0.00% | D |
| Turnover | 0.00 | E |
| Gearing Ratio | 27.51% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - aTyr Pharma, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-10.43%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.88",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "50937604.63",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "190000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-105.32%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-36857.37%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-10.43%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-18.09%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-22.87%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "84.37%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "27.51%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.73 | 160/386 | - | - | - |
| PB | 0.88 | 81/386 | 6.26 | 1.23 | 0.94 |
| PS (TTM) | 268.09 | 278/386 | 461.00 | 409.54 | 372.76 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 11% |
| Overweight | 2 | 22% |
| Hold | 6 | 67% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.48 |
| Highest Target | 20.00 |
| Lowest Target | 1.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ATYR.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ATYR.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ATYR.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ATYR.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**